General contact

Head Office
Novartis International AG
CH-4002 Basel
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 - 17:00, GMT+1
(Central European Time)

Investors

Novartis International AG
Investor Relations
P.O. Box
CH-4002 Basel
Switzerland

+41 61 324 79 44

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Vaccines

Video clips / soundbites

Inspection and Labeling of Celtura, the Novartis cell culture A(H1N1) vaccine.
Inspection and Labeling of Celtura, the Novartis cell culture A(H1N1) vaccine.
B-roll of filling and packaging of Focetria, a Novartis Egg-based H1N1 vaccine.
B-roll of filling and packaging of Focetria, a Novartis Egg-based H1N1 vaccine.
Andrin Oswald, CEO of Novartis Vaccines and Diagnostics — at the Marburg, Germany cell culture vaccine manufacturing facility — discusses the need for ongoing pandemic preparedness.
Andrin Oswald, CEO of Novartis Vaccines and Diagnostics — at the Marburg, Germany cell culture vaccine manufacturing facility — discusses the need for ongoing pandemic preparedness.

Images

Celtura

Celtura labeling
Celtura labeling
Celtura labeling
Celtura labeling
Celtura
Celtura

Fluvirin

Fluvirin multidose viral
Fluvirin multidose viral
Fluvirin syringe
Fluvirin syringe
Fluvirin
Fluvirin

Focetria

Focetria carton vials
Focetria carton vials
Focetria carton syringes
Focetria carton syringes

General

Inspection
Inspection
Inspection
Inspection
You may use the multimedia material provided in this section for commercial purposes only in relation to Novartis. These images must not be modified in any way and each item must have the copyright acknowledgement of Novartis AG (© Novartis AG).